The European Partnership on One Health Antimicrobial Resistance, EUP OHAMR, is launching an international call for projects on 18 November 2025, which will explore new treatments to tackle AMR. The call "Treatments and adherence to treatment protocols", involves 36 funding organisations from 28 different countries with an estimated total call budget of over 28 million Euro. The call is co-funded by the European Union.
Call title: Treatments and adherence to treatment protocols
Focus area: Provide innovative and cost-effective treatment options
Grant form: Project grant
Call opens: 18 November 2025
Call closes: 2 February 2026
Estimated budget: Over 28 million Euros
Please note:
- Only transnational research and innovation projects will be supported.
- An online partner search tool will be available.
- The call will follow a two-step evaluation process (submission of a pre-proposal; successful consortia will be invited to submit a full proposal).
- Pre-proposals and full proposals must be submitted by the project coordinator on the EUP OHAMR on-line submission platform.
- The participation of the different funding organisations listed below is indicative and their participation is not yet confirmed.
Drug-resistant infections are responsible for an increasing number of treatment failures, increased mortality and decreased food productivity. The inappropriate use of antibiotics, poor adherence to prescriptions, and overuse are among the main drivers of AMR, having a detrimental impact on the effectiveness of these critical medicines.
Developing novel treatment protocols or alternative strategies to treat infectious diseases and improving, preserving and reinforcing the clinical efficacy of the current antimicrobial treatments, is vital. It is also necessary to identify the barriers that prevent end users from adhering properly to the existing treatment protocols..
The aim of this first EUP OHAMR Call is to improve the treatment success rates of the patients, animals and plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance in the different One Health settings.
Call topics
Research & innovation proposals submitted under this call must address one of the following topics:
Topic 1
Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
Resistance limits the usability of many commonly-used antibiotics and antifungal agents in Human Health, Animal Health, and Plant Health.
Proposals addressing this topic should identify and develop therapies to be used in combination (combination of different antimicrobials, or combination of an antimicrobial and a non-antimicrobial that improves activity or facilitates a better targeting towards the site of infection) to reduce the development of resistance against antibacterial and antifungal treatments and extend the usability of inexpensive and readily available antimicrobials. These studies should be underpinned by scientific rationale and mechanism of action of these treatments.
In the framework of this topic, improvement of existing combination treatments is eligible (i.e. pharmacokinetics and pharmacodynamics, mode of administration). The choice of the targeted pathogens should be well justified. For the proposals having a Human Health interest, the proposed combination treatment should be directed against one of the bacterial or fungal pathogens included in the WHO priority lists.
Topic 2
Develop tools and methods to improve adherence to treatment protocols.
A low adherence to the treatment protocols by end-users (patients, farmers, citizens) leads to a decreased probability of success and to an increased risk of resistance to antibacterial and antifungal treatments.
Proposals addressing this topic should identify the reasons of poor adherence to treatment protocols (Human, Animal, Plant), and/or develop innovative tools (including digital tools) and methods (including sociological and behavioural approaches) to improve the adherence to treatment protocols and/or test and compare the efficiency of existing or innovative tools and methods on the adherence to treatment protocols.
Engagement with end-users is mandatory. The consideration of vulnerable groups, which often have reduced access to conventional health and care services, is expected.
Topic 3
Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.
Proposals addressing this topic are expected to assess the impact of mechanisms of action, formulations, routes of administration and treatment regimens of antibacterial and antifungal drugs authorized for veterinary and agricultural use on the risk of emergence and transmission of AMR to humans and the environment.
Proposals addressing this topic should also aim to improve the formulation, dosage, delivery, routes of administration and treatment regimens (including pharmacokinetics and pharmacodynamics) currently used in the veterinary and agricultural sector, to decrease the risk of cross-resistance, or transmission to humans and the environment.
The aim is to generate evidence to support policies that restrict certain antimicrobials for exclusive human use and inform policies such as the WHO List of Medically Important Antimicrobials (pdf, who.int).
Composition of the transnational consortium
To be eligible, the submitted pre-/full proposals must respect the following eligibility rules regarding the composition of their consortium. Consortia not respecting the following eligibility rules will be rejected without further review.
- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
- The consortium can include a maximum of six (6) project partners (including non-funded partners).
- The maximum number of partners can be increased to seven (7) if the consortium includes:
- at least one partner from an under-represented country or
- at least one partner where the Principal Investigator meets the definition of an Early-Career Researcher or
- a start-up, SME, or an Industry.
- For the purpose of this call, the under-represented countries are:
- Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Moldova, Poland, and Slovakia.
- A consortium cannot include more than two (2) partners requesting funding from the same funding organisation.
- A principal investigator can coordinate only one (1) submitted pre-proposal/ full proposal.
Early Career Researcher definition
For the purpose of this call, an Early-Career Researcher (ECR) is a PhD holder, up to 8 years after the year of PhD award, holding a position at a recognised institution.
The 8-year period may be extended to allow for career breaks including documented parental leave, positions of trust in trade union organisations and student organisations, mandatory military or civil service, illness (own illness or care for close family members), medical internships or medical fellowship (applies to clinically active professionals). The last two categories may involve periods of up to 24 months each.
Please note that the EUP OHAMR definition of an ECR may differ from the national/regional definition.
Participating countries and funding organisations
There are 36 funding organisations from 28 different countries participating in this call with a total budget of over 28 million Euro. Please note that there may be changes to the list below and that details regarding national eligibility rules will not be published before the call opens.
- Austria, Fonds zur Förderung der Wissenschaftlichen Forschung (FWF)
- Belgium, Belgium Fonds de la Recherche Scientifique (FNRS)
- Belgium, Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO)
- Belgium, Service Public de Wallonie (SPW)
- Canada, Canadian Institutes of Health Research (CIHR)
- Czech Republic, Ministerstvo Zdravotnictvi Ceske Republiky (MZCR)/ Agentura pro zdravotnicky vyzkum (AZVCR)
- Denmark, Innovationsfonden, Innovation Fund Denmark (IFD)
- Estonia, Sihtasutus Eesti Teadusagentuur (ETAG)
- Finland, Suomen Akatemia (AKA)
- France, Agence Nationale de la Recherche (ANR)
- Germany, Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)/ Deutsches Zentrum für Luft- und Raumfahrt Projektträger (DLR-PT)
- Hungary, Nemzeti Kutatási, Fejlesztési Innovációs Hivatal (NKFIH)
- Ireland, Department of Agriculture, Food and the Marine (DAFM)
- Ireland, Taighde Éireann – Research Ireland (TÉ-RI)
- Ireland, The Health Research Board (HRB)
- Israel, Ministry Of Health – Chief Scientist Office (CSO-MOH)
- Italy, Fondazione Regionale per la Ricerca Biomedica (FRRB)
- Italy, Ministero della Salute (MOH-IT)
- Latvia, Latvijas Zinatnes Padome (LZP)
- Lithuania, Lietuvos Mokslo Taryba (LMT)
- Malta, Xjenza Malta (XM)
- Moldova, National Agency for Research and Development (NARD)
- Netherlands, Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)
- Norway, The Research Council of Norway (RCN)
- Poland, Narodowe Centrum Nauki (NCN)
- Portugal, Fundacao para a Ciencia e a Tecnologia (FCT), participation pending
- Slovakia, Centrum Vedecko Technickych Informacii Slovenskej Republiky (CVTI SR)
- South Africa, South African Medical Research Council (SAMRC)
- Spain, Instituto Aragones de Ciencias de la Salud (IACS)
- Spain, Agencia Estatal de Investigación (AEI)
- Spain, Instituto de Salud Carlos III (ISCIII)
- Sweden, Vetenskapsrådet, Swedish Research Council (SRC)
- Switzerland, Schweizerischer Nationalfonds zür Forderung der Wissenschaftlichen Forschung (SNSF)
- Turkiye, Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
- United Kingdom, Medical Research Council – United Kingdom Research and Innovation (MRC – UKRI), Department of Health and Social Care (DHSC), participation pending
- United Kingdom, Innovate UK – United Kingdom Research and Innovation (Innovate UK – UKRI), Department of Health and Social Care (DHSC), participation pending
Call timeline
- 18 November 2025 (11.00 CET): Call opens
- 26 November 2025 (14.00 CET): Webinar for applicants
- 2 February 2026 (13.00 CET): Deadline pre-proposals
- 17 June 2026 (13.00 CEST): Deadline full proposals
- December 2026 – April 2027: Projects start